Micardis

Micardis is an angiotensin II receptor antagonist (ARB) used in the management of hypertension. Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a reduction in arterial blood pressure. Recent studies suggest that telmisartan may also have PPAR-gamma agonistic properties that could potentially confer beneficial metabolic effects.


Most likely, Micardis - a mixture:
Micardis Plus (Hydrochlorothiazide + Telmisartan)

Medicinal name:
  • Hydrochlorothiazide 25 MG / telmisartan 80 MG Oral Tablet [Micardis-HCT]
  • Hydrochlorothiazide 12.5 MG / telmisartan 40 MG Oral Tablet [Micardis-HCT]
  • Telmisartan 40 MG Oral Tablet [Micardis]
  • Telmisartan 80 MG Oral Tablet [Micardis]
  • Telmisartan 20 MG Oral Tablet [Micardis]
  • Hydrochlorothiazide 12.5 MG / telmisartan 80 MG Oral Tablet [Micardis-HCT]

Micardis - Pharmacology:

Micardis interferes with the binding of angiotensin II to the angiotensin II AT1-receptor by binding reversibly and selectively to the receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. Micardis does not inhibit the angiotensin converting enzyme, other hormone receptors, or ion channels.

Micardis mini report

Micardis NDA
NDA - A product marketed under an approved New Drug Application
Micardis HUMAN PRESCRIPTION DRUG
HUMAN PRESCRIPTION DRUG
Micardis global name
telmisartan
Micardis global name
TELMISARTAN
Start - Stop data
START DATA:
2000-Dec-01
Start - Stop data
STOP DATA
not occurred

Micardis for patients

Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to drugs that act on the renin-angiotensin system, and they should also be told that these consequences do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

Symptomatic Hypotension: A patient receiving MICARDIS HCT should be cautioned that lightheadedness can occur, especially during the first days of therapy, and that it should be reported to the prescribing physician. The patients should be told that if syncope occurs, MICARDIS HCT should be discontinued until the physician has been consulted.

All patients should be cautioned that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Potassium Supplements: A patient receiving MICARDIS HCT should be told not to use potassium supplements or salt substitutes that contain potassium without consulting the prescribing physician.

Micardis Interactions

Micardis

Digoxin: When telmisartan was coadministered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. It is, therefore, recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing telmisartan to avoid possible over- or under-digitalization.

Warfarin: Micardis administered for 10 days slightly decreased the mean warfarin trough plasma concentration; this decrease did not result in a change in International Normalized Ratio (INR).

Other Drugs: Coadministration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glibenclamide, simvastatin, hydrochlorothiazide or ibuprofen. Micardis is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19. Micardis is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.

Hydrochlorothiazide: When administered concurrently, the following drugs may interact with thiazide diuretics: Alcohol, barbiturates, or narcotics: Potentiation of orthostatic hypotension may occur.

Antidiabetic drugs (oral agents and insulin): Dosage adjustment of the antidiabetic drug may be required.

Other antihypertensive drugs: Additive effect or potentiation.

Cholestyramine and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Single doses of either cholestyramine or colestipol resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85% and 43%, respectively.

Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia.

Pressor amines (e.g., norepinephrine): Possible decreased response to pressure amines but not sufficient to preclude their use.

Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine): Possible increased responsiveness to the muscle relaxant.

Lithium: Should not generally be given with diuretics. Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity. Refer to the package insert for lithium preparations before use of such preparations with MICARDIS HCT.

Non-steroidal anti-inflammatory drugs: In some patients, the administration of a non-steroidal antiinflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics. Therefore, when MICARDIS HCT and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.

Micardis Contraindications

MICARDIS HCT (telmisartan/hydrochlorothiazide) is contraindicated in patients who are hypersensitive to any component of this product.

Because of the hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.

Manufacturers name:

  • Lake Erie Medical & Surgical Supply DBA Quality Care Products LLC
  • Boehringer Ingelheim Pharmaceuticals, Inc
  • Physicians Total Care, Inc

Generic name, Overdose, Half Life Micardis, Food Interactions, Chemical, etc..

Micardis see also FDA report

Brand Names containing Telmisartan
Cardiovascular